MEDICAL DEVICES · SERVICE DETAILS

PMA Pre-market approval for services

Planning of the division of labour between PMA applications, research and documentation, organization of technical and manufacturing quality information, collaborative submission, review of responses and follow-up of valid scientific evidence on the safety and effectiveness of applied devices.

The applicability of PMA and the evidence required shall be judged by the specific device. The FDA review objective does not amount to a commitment for project approval; The inclusion of clinical research, test execution, examination preparation and post-approval matters shall be agreed separately.

SERVICE OVERVIEW

What does this service help with?

Check the original application or other type of application from the intended use, classification and evidentiary basis to identify the applicant’s rights or authorization of the technical data. An inventory of the evidence of the organization, information gaps, application documents and responses can be made as agreed, and the manufacturing and post-approval requirements can be linked.

WHO MAY NEED IT

Who should consider this service?

A high-risk equipment enterprise and a technical information team need to be assessed or prepared for PMA. Whether the PMA must be used cannot be judged solely on the basis of “innovation” or “no comparable instrument”, but should be verified in conjunction with classification, product history and applicable legislation.

SCOPE & APPROACH

What can PMA support include?

Technical evidence, clinical execution, manufacturing quality, submission and post-approval support of disaggregated scopes, first addressing availability of information and segregation of duties.

01

Applied path and type of application planning

Check classification, use, existing FDA decisions and types of applications to be submitted, and collate applicants, data rights or authorizations and issues requiring prior communication.

02

Clinical and non-clinical evidence gap assessment

Establishing a catalogue of security validity arguments and evidence to reconcile research design, analysis and reporting gaps; Clinical execution, statistics and testing are individually contracted.

03

Organization for Manufacturing, Quality and Labelling Information

Collating product manufacturing, critical processes and quality information, checking labels, uses, risk benefits and consistency of findings, and identifying matters to be supplemented by enterprises.

04

Prior communication and request review

Prepare communication information, questions and application structures as agreed, check current formats, administrative and technical content, attachments and applicable costs, and avoid missing key grounds.

05

Submission and review of responses to questions

Collaboration in submitting applications for application and collating versions of FDA feedback, references to evidence and responses; Additional studies, significant changes in information and additional cycles are evaluated separately.

06

Interlinkage between inspection and post-ratification

Identification of preparation, approval requirements, reporting and change assessment arrangements, where applicable, to identify matters requiring supplemental application or other follow-up.

GET READY

The catalogue of taxonomy, research and manufacturing information is organized first.

The initial assessment focuses on confirming the existence of information, its scope of application and the right of the applicant to use it, and then developing a specific work plan.

  • Product description, adaptation, intended use and classification basis
  • Recorded PMA or other applications, FDA communication and decision
  • Clinical programmes, data, analytical reports and related mandates
  • Non-clinical testing, software, sterilisation and other applicable technical reports
  • Information on manufacturing processes, sites, key processes and quality
  • Label description, risk-benefit documentation and information manager
HOW TO START

From initial review to engagement

STEP 01

Confirm path and access to information

Check product, classification, type of application and technical data authorization base.

STEP 02

Division of planning evidence and project division

Identify clinical, non-clinical, manufacturing quality and documentation gaps, and identify milestones and costs.

STEP 03

Organizational review and submission of application

Alignment of technology, labels and administrative documents, enabling submission and feedback processing according to the applicable format.

STEP 04

Response to follow-up requests

Collaborative review issues, cross-checking, approval conditions and change maintenance, as applicable.

The applicability of PMA and the evidence required shall be judged by the specific device. The FDA review objective does not amount to a commitment for project approval; The inclusion of clinical research, test execution, examination preparation and post-approval matters shall be agreed separately.

TIMING & FEES

Timing and fees

Information reviewed:Fee period: FY 2027, October 1, 2026 through September 30, 2027. For other charges, use the FDA rules as of the review date.

Timing and preparation

Document preparation

Preparation plan for clinical and non-clinical research, data analysis, manufacturing quality information and necessary pre-communication decisions. The assessment of available evidence, delegation of authority and gaps will be followed by agreement on milestones, and research implementation will not be included in a fixed Chargé d ' affaires cycle.

FDA processing

Under MDUFA V, the decision goal for applicable submissions such as original PMAs that do not require advisory committee input is 90% within 180 FDA review days. Check other submission types and those requiring committee input separately. This goal does not guarantee approval within 180 calendar days.

Fee breakdown

FDA fees

FY 2027 Original PMA standard fee US$ 636,732; The applicable small business has been identified as US$ 159,183. (a) The eligibility for the first application is checked separately; There are different fees for supplementary applications and annual reports, which cannot be fully applied to the original application fee.

Service fees

Bids by strategy and evidence assessment, communication information, application organization, submission of responses and range of post-check or post-approval support, indicating whether clinical, statistical and research implementation is separately accounted for.

Other possible costs

The costs of clinical, statistical, test, quality-related technical work, translation etc. are shown separately by range; Supplementary applications and post-approval fees shall be reconciled separately with the fiscal year according to the type of submission.

OFFICIAL SOURCES

FDA Official Basis and Check Date

Data check: 2026-11-06. Specific application conditions, formats and costs should be identified in conjunction with the current FDA rules and project facts.

START WITH YOUR PRODUCT

The classification of products is checked against the available scientific evidence.

Provide a catalogue of information on uses, classification bases, research and manufacturing, confirming type of application, technical gaps, division of labour and quotations.